PMID- 37189777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230519
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 4
DP  - 2023 Apr 12
TI  - New Insights into the Use of Liraglutide-Impact on Cardiovascular Risk and 
      Microvascular Outcomes.
LID - 10.3390/biomedicines11041159 [doi]
LID - 1159
AB  - Despite the availability of many glucose-lowering drugs, patients with type 2 
      diabetes mellitus (T2DM) often do not achieve the desired effect, and 
      cardiovascular complications remain the leading cause of death in this group of 
      patients. Recently, more and more attention has been paid to the properties of 
      drugs, with particular emphasis on the possibility of reducing cardiovascular 
      risk. One of them is liraglutide, which belongs to long-acting analogs of 
      glucagon-like peptides-1 (GLP-1); it imitates incretins and causes an increase in 
      insulin secretion. The current study focused on analyzing the efficacy and safety 
      of liraglutide, as well as its impact on microvascular and cardiovascular 
      outcomes in the treatment of patients with T2DM. Hyperglycemia-induced 
      endothelial dysfunction, which is known to play a key role in maintaining 
      cardiovascular homeostasis, is common in diabetes. Liraglutide reduces 
      endothelial dysfunction by reversing damage to endothelial cells. By reducing the 
      generation of reactive oxygen species (ROS), thereby affecting Bax, Bcl-2 protein 
      levels, and restoring signaling pathways, Liraglutide reduces oxidative stress, 
      inflammation, and prevents endothelial cell apoptosis. Liraglutide has beneficial 
      effects on the cardiovascular system; patients with high cardiovascular risk 
      particularly benefit from treatment, as it reduces their major adverse 
      cardiovascular event (MACE) rate, which takes into account cardiovascular death, 
      stroke, and non-fatal myocardial infarction. Liraglutide reduces the occurrence 
      and progression of nephropathy, which is one of the most common microvascular 
      complications of diabetes.
FAU - Wronka, Magdalena
AU  - Wronka M
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Krzeminska, Julia
AU  - Krzeminska J
AUID- ORCID: 0000-0003-4463-2731
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Mlynarska, Ewelina
AU  - Mlynarska E
AUID- ORCID: 0000-0002-6799-4746
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
FAU - Rysz, Jacek
AU  - Rysz J
AD  - Department of Nephrology, Hypertension and Family Medicine, Medical University of 
      Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
FAU - Franczyk, Beata
AU  - Franczyk B
AD  - Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 
      90-549 Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230412
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10136170
OTO - NOTNLM
OT  - cardiovascular risk
OT  - glucagon-like peptides-1
OT  - liraglutide
OT  - microvascular
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/16 06:42
MHDA- 2023/05/16 06:43
PMCR- 2023/04/12
CRDT- 2023/05/16 01:11
PHST- 2023/03/19 00:00 [received]
PHST- 2023/04/06 00:00 [revised]
PHST- 2023/04/10 00:00 [accepted]
PHST- 2023/05/16 06:43 [medline]
PHST- 2023/05/16 06:42 [pubmed]
PHST- 2023/05/16 01:11 [entrez]
PHST- 2023/04/12 00:00 [pmc-release]
AID - biomedicines11041159 [pii]
AID - biomedicines-11-01159 [pii]
AID - 10.3390/biomedicines11041159 [doi]
PST - epublish
SO  - Biomedicines. 2023 Apr 12;11(4):1159. doi: 10.3390/biomedicines11041159.